Mechanism by which metformin reduces glucose production in type 2 diabetes

Diabetes

Volumn 49, Issue 12, 2000, Pages 2063-2069

  Hundal, Ripudaman S ^a   Krssak, Martin ^a   Dufour, Sylvie ^a   Laurent, Didier ^a   Lebon, Vincent ^a   Chandramouli, Visvanathan ^b   Inzucchi, Silvio E ^a   Schumann, William C ^b   Petersen, Kitt F ^a   Landau, Bernard R ^b   Shulman, Gerald I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; METFORMIN;

ADULT; ARTICLE; BODY MASS; CARBON NUCLEAR MAGNETIC RESONANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HUMAN; HYPERGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0033673203     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.49.12.2063     Document Type: Article

References (44)

1. Metformin
2. Metformin: A review of its metabolic effects
3. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
4. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus
5. Metformin: Effects upon postabsorptive intrahepatic carbohydrate fluxes
6. 13C NMR
7. Contributions of gluconeogenesis to glucose production in the fasted state
8. 2O for estimating rates of gluconeogenesis: Application to the fasted state
9. 13C nuclear magnetic resonance spectroscopy
10. 13C NMR measurements of liver glycogen in vivo
11. L-(+)- Lactate determination with lactic dehydrogenase
12. A microfluorometric method for the determination of flee fatty acids in plasma
13. Human serum cholesterol synthesis measured with the deuterium label
14. A micromethod for measurement of deuterium bound to carbon 6 of glucose to quantify gluconeogenesis in vivo
15. Blood and other bodily fluids
16. Quantitative comparison of pathways of hepatic glycogen repletion in fed and fasted humans
17. Direct analysis of 18 O in glucose by mass spectrometry
18. The triumvirate: β-cell, muscle, liver, a collusion responsible for NIDDM
19. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus
20. Relationship between hepatic glucose production and fasting glucose concentration in patients with NIDDM
21. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus
22. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
23. Increased rate of gluconeogenesis in type II diabetes mellitus
24. Efficacy of metformin in type-II diabetes: Results of a double-blind, placebo-controlled, doseresponse trial
25. Efficacy of metformin in NIDDM patients poorly controlled on diet alone or diet plus sulfonylurea
26. Contributions of net hepatic glycogenolysis and gluconeogenesis to glucose production in Cirrhosis
27. Liver glycogen turnover in fed and fasted humans
28. The roles of insulin and glucagon in the regulation of hepatic glycogen synthesis and turnover in humans
29. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans
30. A critical evaluation of mass isotopomer distribution analysis of gluconeogenesis in vivo
31. Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis: Substrate cycling between glycerol and triose phosphates in liver
32. A limitation in the use of mass isotopomer distributions to measure gluconeogenesis in fasting humans
33. Limitations of the mass isotopomer distribution analysis of glucose to study gluconeogenesis: Heterogeneity of glucose labeling in incubated hepatocytes
34. Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver
35. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes
36. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin
37. Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects
38. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients
39. Acute antihyperglycemic mechanisms of metformin in NIDDM: Evidence for suppression of lipid oxidation and hepatic glucose production
40. Combined metformin-sulfonylurea treatment of patients with noninsulin-dependent diabetes in fair to poor glycemic control
41. The role of fatty acids in mediating the effects of peripheral insulin on hepatic glucose production in the conscious dog
42. In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans
43. Splanchnic and leg exchanges of glucose, amino acids and flee fatty acids during exercise in diabetes mellitus
44. Central role of the adipocyte in insulin resistance